

Mission accomplished: full house secured at Cambridge life sciences hub

2 Oct 2026 | 08:15 | London | by Charlie Schouten

Pair of lettings take first phase Foxton scheme to full occupancy



- **What** Mission Street and BGO have secured two tenants at its life sciences hub in Cambridge
- **Why** Both are expanding their footprint following significant growth
- **What next** Deals take the first phase of the scheme to full occupancy

Mission Street and BGO have agreed two deals at The Press in Cambridge, taking the first phase of the science and innovation campus to full occupation,

Green Street News can reveal.

The lettings to battery technology and biotech companies Horizn and Syndex Bio total 15,000 sq ft, and represent full occupancy of the first phase of the scheme in Foxton, which sits within Cambridge's southern life sciences cluster.

Founded in 2013, Horizn's battery storage technologies use advanced polymers derived from contact lens material. Led by chief executive Jane Hunter, the firm is relocating from Chesterford Research Park, taking 10,000 sq ft to further commercialise its water-based zinc battery systems, which have both commercial and industrial applications.

Syndex Bio uses its patented mcPCR technology to improve early disease detection and recurrence monitoring. The company was established in 2022 by Geoff Smith, previously global head of technology development at the genomics giant Illumina.

After closing its oversubscribed seed financing round in February 2025, Syndex Bio is expanding by an additional 5,000 sq ft onsite, having quadrupled its headcount since moving to The Press 18 months ago.

The Press was delivered with the backing of BGO and includes lab and innovation space within a converted printing press dating from 1909.

Artem Korolev, founder and chief executive of Mission Street, said: "We are excited to welcome Horizn to The Press and to support Syndex Bio's expansion. These moves support the thesis of The Press being the best-connected location in the south Cambridge cluster and builds on the wider market momentum including GSK's relocation to the Biomedical Campus, accessible from the Press via an eight-minute direct train.

"Our wider campus, including a new cafe opening, has recently completed – providing a high-quality environment suitable for a range of innovation uses, from new build fitted labs through to mid-tech. We look forward to welcoming our next occupiers."

Jane Hunter, chief executive at Horizn, said: "I am delighted to lead Horizn through this exciting phase as the company starts to deploy batteries with customers for testing in preparation for building out a pilot production line. Our expertise in polymer science has led to a timely breakthrough for the battery industry, enabling novel battery chemistries to address gaps that lithium-ion cannot meet.

"The Horizn team is scaling the business and technology at pace as we work to make our unique battery commercially available in time to meet this market need."

Geoff Smith, founder and chief executive of Syndex Bio, added: "Our mcPCR technology has made fantastic progress in the past 18 months, and we are delighted to be able to expand our footprint at The Press in Foxton to accommodate our next phase of growth."